Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

FCBA Annual Bench & Bar Conference

Summary

Speakers

Mark J. Abate

Related Content

The Chevron Doctrine Is Dead. What Are the Implications for Business?

USPTO Issues New Guidance on Patenting AI-Assisted Inventions

The USPTO’s Increasing Focus on FDA Submissions and the Duty of Disclosure

Chief Judge of Western District of Texas Changes Waco Patent Case Assignment System

Fintiv 2.0: USPTO Director Issues Guidance Softening Risk of Discretionary Denial

Federal Circuit Clarifies Standard for Fair and Reasonable Exercise of Jurisdiction Based on Demand Letters

Aren’t You Glad 2020 Is Over? A Look Back (and Ahead)

Federal Circuit Narrows Venue for Patent Infringement Suits Under the Hatch-Waxman Act

Best Lawyers Best Law Firms 2025 Names Goodwin Biotechnology and Life Sciences Law Firm of the Year for the Eighth Time and Recognizes 55 Practice Areas

ACI's 4th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA

Goodwin Advises Curon Biopharmaceutical in Acquisition of CN201 by Merck for $700 Million Upfront Plus up to $600 Million Milestones

Sedona Conference WG9/10 Annual Meeting 2024

The Best Lawyers in America 2025 Recognizes 312 Goodwin Lawyers

Benchmark Litigation Names Fourteen Goodwin Partners to 40 & Under Hot List 2024

LAIPLA's Patents On Tap

Chevron Overturned: Implications of Loper Bright and Relentless for Life Sciences

Patent Litigation